How it works

A disciplined, repeatable analysis pipeline.

A full company valuation follows the same rigorous steps — a structured workflow, not ad-hoc prompting. Here is what happens between your question and the sourced report.

The five stages

These five stages are the full company-valuation pipeline. Stock screening runs a lighter triage-to-shortlist pass first, then feeds the names it likes into this same pipeline.

    Ask
    01
    Start in plain language — a ticker or a company name. No query syntax, no setup.
    Parallel specialist analysis
    02
    Independent specialists work at the same time, each on one dimension of the thesis: the macro regime, the company's fundamentals and business quality, the sector-specific lens, and intrinsic value.
    Adversarial challenge
    03
    A dedicated stage argues the other side — disconfirming evidence, historical analogues, hidden assumptions and second-order effects — and flags gaps by severity. A critical gap pauses the run for your decision.
    Board synthesis
    04
    Where enabled, independent frontier models review the completed analysis and reconcile it into a single second-opinion view — depth without a single black box.
    Sourced report + PDF
    05
    A long-form, cited write-up with multi-horizon price targets — streamed live as it is written and exportable as a PDF.

Workflow map

Single-name decision

Company Valuation

When you already have a company in mind and need a full investment view.

Output: A sourced report with BUY/HOLD/PASS call, scenarios, peer context, risks, 12-month/3-year/5-year targets and PDF export.
Find candidates first

Stock Screening

When you want FinBro to surface names that clear a value bar before you choose what to study.

Output: A conviction-weighted shortlist that can hand promising names into a full company valuation.

Specialist sector coverage

The company and sector lenses are handled by specialists tuned to how each sector actually trades — banks aren’t valued like software, and defense isn’t read like retail. The breadth spans:

Pharma & biotechBanks & financialsInsuranceDefense & aerospaceSemiconductorsTech & softwareEnergy & midstreamREITsRetailLogistics & transportCommodities & goldBitcoin

The adversarial challenge

Before you read a word, a dedicated stage tries to break the thesis. It searches for disconfirming evidence, checks the case against historical analogues, audits the hidden assumptions, and traces the second-order effects — then classifies every gap it finds by severity.

Disconfirming evidence

Looks for facts that weaken the thesis instead of only supporting it.

Historical analogues

Checks whether similar setups ended differently than the headline story suggests.

Hidden assumptions

Calls out the growth, margin, rate, cycle or execution assumptions the case depends on.

Second-order effects

Tracks what can happen after the obvious first move — competitors, regulation, capital costs and customer behavior.

Severity gate
A critical gap doesn’t get papered over — it pauses the run and hands the decision back to you: refocus the analysis, proceed with the caveat on the record, or stop. The product won’t hand you a thesis it hasn’t tried to break.
Refocus
Ask for a tighter run that closes the gap.
Proceed
Keep the caveat visible in the final report.
Stop
Do not turn a broken thesis into a confident answer.

Board synthesis

Where enabled, independent frontier models each review the completed analysis and reconcile it into a single second-opinion view. No model is named and none has the last word — the value is the cross-check between independent perspectives, not any one brand. Because it can be turned on or off per environment, treat it as the synthesis approach rather than a guarantee on every run.

Valuation methods

Intrinsic value is built with the method that actually fits the business, not a single template forced onto every name:

Discounted cash flow
Cash-generative businesses
Projects and discounts future free cash flow — the default where cash flows are forecastable.
Earnings power
Cyclical or mature companies
Values normalized, sustainable earnings without banking on future growth.
Asset-based
Banks, insurers and asset-heavy names
Values the balance sheet directly — fitting for asset-heavy and financial businesses.
Relative
Comparable peer sets
Benchmarks the multiple against peers and the sector as a cross-check on absolute value.
Dividend discount
Income and dividend-quality cases
Values the stream of dividends for stable, income-paying names.

Every valuation resolves to multi-horizon price targets — 12-month, 3-year and 5-year — in USD, with an EUR conversion where it is relevant.

Keep reading

Read the docs

How to run each workflow, step by step.

See the data

What every run is built on, and how it is cited.